Cargando…
Correction: Characterization of CDK(5) inhibitor, 20-223 (aka CP668863) for colorectal cancer therapy
Autores principales: | Robb, Caroline M., Kour, Smit, Contreras, Jacob I., Agarwal, Ekta, Barger, Carter J., Rana, Sandeep, Sonawane, Yogesh, Neilsen, Beth K., Taylor, Margaret, Kizhake, Smitha, Thakare, Rhishikesh N., Chowdhury, Sanjib, Wang, Jing, Black, Jennifer D., Hollingsworth, Michael A., Brattain, Michael G., Natarajan, Amarnath |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7321697/ https://www.ncbi.nlm.nih.gov/pubmed/32637035 http://dx.doi.org/10.18632/oncotarget.27403 |
Ejemplares similares
-
Characterization of CDK(5) inhibitor, 20-223 (aka CP668863) for colorectal cancer therapy
por: Robb, Caroline M., et al.
Publicado: (2017) -
CDK5 Inhibitor Downregulates Mcl-1 and Sensitizes Pancreatic Cancer Cell Lines to Navitoclax
por: Kour, Smit, et al.
Publicado: (2019) -
Stapling proteins in the RELA complex inhibits TNFα-induced nuclear translocation of RELA
por: Kour, Smit, et al.
Publicado: (2021) -
Characterization of Promiscuous Binding of Phosphor Ligands to Breast-Cancer-Gene 1 (BRCA1) C-Terminal (BRCT): Molecular Dynamics, Free Energy, Entropy and Inhibitor Design
por: You, Wanli, et al.
Publicado: (2016) -
Systemic Administration of a Brain Permeable Cdk5 Inhibitor Alters Neurobehavior
por: Umfress, Alan, et al.
Publicado: (2022)